Acute myeloid leukemia (AML) is a systemic, heterogeneous hematologic malignancy with poor overall survival. While some malignancies have seen improvements in clinical outcomes with immunotherapy, success of these agents in AML remains elusive. Despite limited progress, stem cell transplantation and donor lymphocyte infusions show that modulation of the immune system can improve overall survival of AML patients. Understanding the causes of immune evasion and disease progression will identify potential immune-mediated targets in AML. This review explores immunosuppressive mechanisms that alter T-cell-mediated immunity in AML.

中文翻译：

---

急性髓系白血病中 T 细胞介导的免疫力的改变。

急性髓性白血病 (AML) 是一种全身性、异质性血液系统恶性肿瘤，总体生存率很低。虽然一些恶性肿瘤已经通过免疫疗法改善了临床结果，但这些药物在 AML 中的成功仍然难以捉摸。尽管进展有限，但干细胞移植和供体淋巴细胞输注表明免疫系统的调节可以提高 AML 患者的总体存活率。了解免疫逃避和疾病进展的原因将确定 AML 中潜在的免疫介导靶点。本综述探讨了改变 AML 中 T 细胞介导免疫的免疫抑制机制。